Table 2 An overview of various clinical trials examining CAR-Ts against various target antigens for the treatment of solid tumours, including TNBC
From: Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer
Target antigen | ClinicalTrials.gov identifier | Phase | Participants | Source | Start-completion date |
|---|---|---|---|---|---|
NKG2D ligand | NCT04107142 | I | 10 | Allogeneic | 2019–2021 |
ROR1 | NCT02706392 | I | 21 | Allogeneic | 2016–2021 |
c-Met | NCT01837602 NCT03060356 | I Early I | 6 | Allogeneic | 2013–2018 2016–2020 |
Mesothelin | NCT01355965 NCT02580747 NCT02792114 NCT02414269 | I I I I/II | 77 18 20 186 113 | Allogeneic | 2011–2015 2015–2018 2016–2023 2015–2024 |
MUC1 | NCT02587689 | I/II | 20 | Allogeneic | 2015–2018 |
A cleaved form of MUC1 | NCT04020575 | I | 69 | Allogeneic | 2020–2035 |
TnMUC1 | NCT04025216 | I | 112 | Allogeneic | 2019–2036 |